Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Janssen Research & Development, LLC
Novartis
Hoffmann-La Roche
Bristol-Myers Squibb
Incyte Corporation
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
Hoffmann-La Roche
Institut du Cancer de Montpellier - Val d'Aurelle
University of Wisconsin, Madison